Eric Ian Marks MD
Assistant Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7012
Hematology & Medical Oncology
Dr. Eric Marks is an Assistant Professor of Medicine at Boston University School of Medicine. He currently specializes in gastrointestinal oncology and sarcomas. Dr. Marks graduated from the University of Massachusetts and subsequently pursued medical school and a residency in Internal Medicine at Pennsylvania State University. He then completed his fellowship in hematology and medical oncology at the Warren Alpert Medical School of Brown University, where he published several studies focused on gastrointestinal malignancies.
Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. Am J Clin Oncol. 2021 02 01; 44(2):68-73. PMID: 33298767.Published on 1/1/2020
Marks EI, Brown VS, Dizon DS. Am J Clin Oncol. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma. 2020; 43(2):139-145.Published on 1/1/2019
Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro B. ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. Oncotarget. 2019; 10:245-251.Published on 1/1/2019
Marks EI, Ollila TA. Acanthocytosis causing chronic hemolysis in a patient with advanced cirrhosis. Blood. 2019; 133:1518.Published on 9/29/2018
Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhairu V, Marks E, Richardson AE, Krecko L, Ali A, Koestler W, Esteva FJ, Leeming DJ, Karsdal MA, Willumsen N. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 2018 12 01; 143(11):3027-3034. PMID: 29923614.Published on 1/1/2017
Yacur M, Marks EI, Suleski J, Joshi M. Expression of Beta-Human Chorionic Gonadotropin (BetaHCG) in Transitional Cell Carcinoma. Annals of Carcinogenesis. 2017; 2(2):1012-1016.Published on 1/28/2016
Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol. 2016 Jan 28; 22(4):1335-47. PMID: 26819503.Published on 1/1/2016
Marks EI, Yee NS. World J of Gastroenterol. Molecular genetics and targeted therapeutics in biliary tract carcinoma. 2016; 22(4):1335-1347.Published on 11/15/2015
Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J Gastrointest Oncol. 2015 Nov 15; 7(11):338-46. PMID: 26600933.Published on 1/1/2015
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015; 16(12):1710-9. PMID: 26561209.